As of November 6, 2026, Eledon Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: ELDN); its largest reported holder is BVF Partners, with 9.99% on Schedule 13G/A of May 15, 2026, then Matthew D. Perry (5.98%). The largest insider holding is BVF GP Holdings LLC, a 10% owner, with 220,460 shares (0.27% of shares outstanding), per Form 4 of October 31, 2024 (Schedule 13G/A, May 15, 2026).
Is this your company?
About to sign with, pay or invest in Eledon Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Eledon Pharmaceuticals, Inc. a real, registered company?
- Eledon Pharmaceuticals Inc files with the SEC under CIK 1404281 (its SEC filings).
- Its shares are listed under the ticker ELDN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Irvine, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Eledon Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vanguard (filed 2026-07-31).
Who are Eledon Pharmaceuticals, Inc.'s owners and officers?
Eledon Pharmaceuticals, Inc.: incorporated in Delaware; business address in Irvine, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-30).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-05-23)
- : Executive Officer (Form D, 2024-05-23)
- : Executive Officer, Director (Form D, 2024-05-23)
- : Executive Officer (Form D, 2024-05-23)
- : Director (Form D, 2024-05-23)
- : Director (Form D, 2024-05-23)
- : Director (Form D, 2024-05-23)
- : Director (Form D, 2024-05-23)
- : Director (Form D, 2024-05-23)
- : Director (Form D, 2024-05-23)
- : Director (Form D, 2024-05-23)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-30 | Vanguard Capital Management | 4.87% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.05% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 5.8% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Ra Capital Management, L.P. | 0% |
| Schedule 13G/A, 2026-02-13 | Coastlands Capital LP | 4.99% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 4.6% |
| Schedule 13G, 2025-11-24 | Matthew D. Perry | 5.98% |
| Schedule 13G, 2025-07-29 | The Vanguard Group | 5.54% |
| Schedule 13G, 2025-07-17 | Blackrock, Inc. | 5.4% |
Questions about who owns Eledon Pharmaceuticals, Inc.
Who owns Eledon Pharmaceuticals, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Eledon Pharmaceuticals, Inc.: Bvf Partners L P/Il (9.99%, Schedule 13G/A, filed 2026-05-15), Matthew D. Perry (5.98%, Schedule 13G, filed 2025-11-24) and Blackrock, Inc. (5.8%, Schedule 13G, filed 2026-04-27).
Who are the largest shareholders of Eledon Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Eledon Pharmaceuticals, Inc. on this page are Bvf Partners L P/Il (9.99%), Matthew D. Perry (5.98%) and Blackrock, Inc. (5.8%).
When did Bvf Partners L P/Il buy into Eledon Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bvf Partners L P/Il on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Eledon Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Eledon Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eledon Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Eledon Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- BVF GP Holdings LLC, a 10% owner: 220,460 shares (0.27% of shares outstanding), on a joint filing (Form 4, 2024-10-31).
- BVF I GP LLC: 220,460 shares (0.27% of shares outstanding), on a joint filing (Form 4, 2024-10-31).
- , a 10% owner: 220,460 shares (0.27% of shares outstanding), on a joint filing (Form 4, 2024-10-31).
- Biotechnology Value Fund LP: 220,460 shares (0.27% of shares outstanding), on a joint filing (Form 4, 2024-10-31).
- Biotechnology Value Fund II LP: 220,460 shares (0.27% of shares outstanding), on a joint filing (Form 4, 2024-10-31).
Shares outstanding: 81,261,152 as of 2026-08-10, from the company's latest SEC cover page.
How much has Eledon Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-05-23 | $50M | not stated |
| Form D, 2023-05-22 | $35M | not stated |
Keep reading
More on Eledon Pharmaceuticals, Inc. and the records around it.
Eledon Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/eledon-pharmaceuticals